Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SV2A Density in Cannabis Use Disorder
NCT05472818Phase 1Completed
- Sponsor
- Yale University
- Start
- Apr 2022
- Primary completion
- Apr 2026
- Countries
- 1
01
Overview
Phase 1, open-label trial (2 arms), sponsored by Yale University. Primary endpoint: Hippocampal SV2A synaptic density at 4 weeks. Started Apr 2022; status: completed.
Beyond the preview
Go deeper on NCT05472818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05472818.